SC
Stempoint Capital Portfolio holdings
AUM
$311M
This Quarter Return
+5.14%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$399M
AUM Growth
+$399M
(+20%)
Cap. Flow
+$70M
Cap. Flow
% of AUM
17.55%
Top 10 Holdings %
Top 10 Hldgs %
51.04%
Holding
75
New
22
Increased
19
Reduced
6
Closed
24
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$15.1M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$14.7M |
| 3 |
Nuvalent
NUVL
|
$11.4M |
| 4 |
Immunovant
IMVT
|
$11.1M |
| 5 |
Alkermes
ALKS
|
$10.6M |
Top Sells
| 1 |
Arcutis Biotherapeutics
ARQT
|
$17.8M |
| 2 |
Amicus Therapeutics
FOLD
|
$15.8M |
| 3 |
Applied Therapeutics
APLT
|
$13.2M |
| 4 |
AUTL
Autolus Therapeutics
AUTL
|
$9.5M |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$7.06M |
Sector Composition
| 1 | Healthcare | 99.62% |
| 2 | Financials | 0.38% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Syndax Pharmaceuticals
SNDX
$1.41B
| $38M | 9.48% | 2,872,601 +1,141,410 | +66% | +$15.1M |
|
2
Roivant Sciences
ROIV
$8.15B
| $32.1M | 8.01% | 2,712,778 -57,041 | -2% | -$675K |
|
|
3
Immunovant
IMVT
$2.56B
| $27.7M | 6.92% | 1,118,508 +447,507 | +67% | +$11.1M |
|
4
Merus
MRUS
$4.98B
| $25.9M | 6.45% | 614,812 +193,590 | +46% | +$8.14M |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $16.2M | 4.05% | 317,060 +103,245 | +48% | +$5.28M |
|
|
6
Xenon Pharmaceuticals
XENE
$2.98B
| $14.7M | 3.68% | +375,845 | New | +$14.7M |
|
7
Incyte
INCY
$16.5B
| $13.4M | 3.34% | 193,623 +64,133 | +50% | +$4.43M |
|
|
8
Alkermes
ALKS
$4.78B
| $12M | 2.99% | 416,968 +368,050 | +752% | +$10.6M |
|
9
Denali Therapeutics
DNLI
$2.23B
| $11.9M | 2.97% | 584,328 +302,278 | +107% | +$6.16M |
|
10
Rhythm Pharmaceuticals
RYTM
$6.85B
| $11.6M | 2.91% | 208,016 +166,748 | +404% | +$9.33M |
|
|
11
Nuvalent
NUVL
$5.52B
| $11.4M | 2.84% | +145,234 | New | +$11.4M |
|
|
CNTA
12
Centessa Pharmaceuticals
CNTA
$2.25B
| $10.8M | 2.68% | 641,964 +558,302 | +667% | +$9.35M |
|
13
Praxis Precision Medicines
PRAX
$958M
| $10.3M | 2.58% | 134,178 -39,856 | -23% | -$3.07M |
|
14
Bristol-Myers Squibb
BMY
$96B
| $9.39M | 2.34% | 166,068 -109,235 | -40% | -$6.18M |
|
15
Wave Life Sciences
WVE
$1.53B
| $8.92M | 2.23% | 721,209 +421,209 | +140% | +$5.21M |
|
16
Revolution Medicines
RVMD
$7.1B
| $8.47M | 2.11% | 193,535 +176,881 | +1,062% | +$7.74M |
|
17
KalVista Pharmaceuticals
KALV
$678M
| $8.41M | 2.1% | +992,803 | New | +$8.41M |
|
18
Janux Therapeutics
JANX
$1.37B
| $7.81M | 1.95% | 145,876 +96,461 | +195% | +$5.16M |
|
19
Insmed
INSM
$28.8B
| $7.36M | 1.84% | +106,610 | New | +$7.36M |
|
20
Scholar Rock
SRRK
$3.14B
| $7.19M | 1.79% | +166,307 | New | +$7.19M |
|
21
Iovance Biotherapeutics
IOVA
$807M
| $7.03M | 1.75% | +949,401 | New | +$7.03M |
|
22
BioNTech
BNTX
$24B
| $7M | 1.75% | +61,403 | New | +$7M |
|
|
23
Arcutis Biotherapeutics
ARQT
$1.86B
| $6.98M | 1.74% | 500,966 -1,277,352 | -72% | -$17.8M |
|
24
Biohaven
BHVN
$1.63B
| $6.96M | 1.74% | 186,413 -30,027 | -14% | -$1.12M |
|
25
VistaGen Therapeutics
VTGN
$102M
| $5.95M | 1.48% | 2,328,492 +481,700 | +26% | +$1.23M |
|